Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

2.50
Hdl Handle:
http://hdl.handle.net/10541/88025
Title:
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Authors:
Van Glabbeke, Martine M; Van Oosterom, A; Oosterhuis, J W; Mouridsen, Henning; Crowther, Derek; Somers, R; Verweij, Jaap; Santoro, A; Buesa, J; Tursz, T
Abstract:
PURPOSE: A total of 2,185 patients with advanced soft tissue sarcomas who had been treated in seven clinical trials investigating the use of doxorubicin- or epirubicin-containing regimens as first-line chemotherapy were studied in this prognostic-factor analysis. PATIENTS AND METHODS: Overall survival time (median, 51 weeks) and response to chemotherapy (26% complete response or partial response) were the two end points. The cofactors were sex; age; performance status; prior therapies; the presence of locoregional or recurrent disease; lung, liver, and bone metastases at the time of entry onto the trial; long time period between the initial diagnosis of sarcoma and entry onto the study; and histologic type and grade. RESULTS: Univariate analyses showed (a) a significant, favorable influence of good performance status, young age, and absence of liver metastases on both survival time and response rate, (b) a significant, favorable influence of low histopathologic disease grade on survival time, despite a significantly lower response rate, (c) increased survival time for patients with a long time period between the initial diagnosis of sarcoma and entry onto the study, despite equivalent response rates, and (d) increased survival time with liposarcoma or synovial sarcoma, a decreased survival time with malignant fibrous histiocytoma, a lower response rate with leiomyosarcoma, and a higher response rate with liposarcoma (P < .05 for all log-rank and chi2 tests). The Cox model selected good performance status (P < .0001), absence of liver metastases (P = .0001), low histopathologic grade (P = .0002), long time lapse since initial diagnosis (P = .0004), and young age (P = .0045) as favorable prognostic factors of survival time. The logistic model selected absence of liver metastases (P < .0001), young age (P = .0024), high histopathologic grade (P = .0051), and liposarcoma (P = .0065) as favorable prognostic factors of response rate. CONCLUSION: This analysis demonstrates that for advanced soft tissue sarcoma, response to chemotherapy is not predicted by the same factors as is overall survival time. This needs to be taken into account in the interpretation of trials assessing the value of new agents for this disease on the basis of response to treatment.
Affiliation:
European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium. mvg@eortc.be
Citation:
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. 1999, 17 (1):150-7 J. Clin. Oncol.
Journal:
Journal of Clinical Oncology
Issue Date:
Jan-1999
URI:
http://hdl.handle.net/10541/88025
PubMed ID:
10458228
Type:
Article
Language:
en
ISSN:
0732-183X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorVan Glabbeke, Martine Men
dc.contributor.authorVan Oosterom, Aen
dc.contributor.authorOosterhuis, J Wen
dc.contributor.authorMouridsen, Henningen
dc.contributor.authorCrowther, Dereken
dc.contributor.authorSomers, Ren
dc.contributor.authorVerweij, Jaapen
dc.contributor.authorSantoro, Aen
dc.contributor.authorBuesa, Jen
dc.contributor.authorTursz, Ten
dc.date.accessioned2009-12-15T16:01:08Z-
dc.date.available2009-12-15T16:01:08Z-
dc.date.issued1999-01-
dc.identifier.citationPrognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. 1999, 17 (1):150-7 J. Clin. Oncol.en
dc.identifier.issn0732-183X-
dc.identifier.pmid10458228-
dc.identifier.urihttp://hdl.handle.net/10541/88025-
dc.description.abstractPURPOSE: A total of 2,185 patients with advanced soft tissue sarcomas who had been treated in seven clinical trials investigating the use of doxorubicin- or epirubicin-containing regimens as first-line chemotherapy were studied in this prognostic-factor analysis. PATIENTS AND METHODS: Overall survival time (median, 51 weeks) and response to chemotherapy (26% complete response or partial response) were the two end points. The cofactors were sex; age; performance status; prior therapies; the presence of locoregional or recurrent disease; lung, liver, and bone metastases at the time of entry onto the trial; long time period between the initial diagnosis of sarcoma and entry onto the study; and histologic type and grade. RESULTS: Univariate analyses showed (a) a significant, favorable influence of good performance status, young age, and absence of liver metastases on both survival time and response rate, (b) a significant, favorable influence of low histopathologic disease grade on survival time, despite a significantly lower response rate, (c) increased survival time for patients with a long time period between the initial diagnosis of sarcoma and entry onto the study, despite equivalent response rates, and (d) increased survival time with liposarcoma or synovial sarcoma, a decreased survival time with malignant fibrous histiocytoma, a lower response rate with leiomyosarcoma, and a higher response rate with liposarcoma (P < .05 for all log-rank and chi2 tests). The Cox model selected good performance status (P < .0001), absence of liver metastases (P = .0001), low histopathologic grade (P = .0002), long time lapse since initial diagnosis (P = .0004), and young age (P = .0045) as favorable prognostic factors of survival time. The logistic model selected absence of liver metastases (P < .0001), young age (P = .0024), high histopathologic grade (P = .0051), and liposarcoma (P = .0065) as favorable prognostic factors of response rate. CONCLUSION: This analysis demonstrates that for advanced soft tissue sarcoma, response to chemotherapy is not predicted by the same factors as is overall survival time. This needs to be taken into account in the interpretation of trials assessing the value of new agents for this disease on the basis of response to treatment.en
dc.language.isoenen
dc.subjectSoft Tissue Canceren
dc.subject.meshAdult-
dc.subject.meshAnalysis of Variance-
dc.subject.meshAntibiotics, Antineoplastic-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDoxorubicin-
dc.subject.meshEpirubicin-
dc.subject.meshHumans-
dc.subject.meshLogistic Models-
dc.subject.meshMiddle Aged-
dc.subject.meshPrognosis-
dc.subject.meshRetrospective Studies-
dc.subject.meshSoft Tissue Neoplasms-
dc.subject.meshSurvival Rate-
dc.titlePrognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.en
dc.typeArticleen
dc.contributor.departmentEuropean Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium. mvg@eortc.been
dc.identifier.journalJournal of Clinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.